Key result
A panel of immunohistochemical markers can identify individual small blue round cell tumors (rhabdomyosarcoma, PNET/Ewings sarcoma, neuroblastoma, and DSRCT) with high sensitivity and specificity.
Why the study?
Can immunohistochemical markers accurately categorize small blue round cell tumors in pediatric patients?
Can immunohistochemical markers accurately categorize small blue round cell tumors in pediatric patients?
Immunohistochemical markers such as Myogenin, FLI-1, and WT-1 provide high sensitivity and specificity for categorizing pediatric small blue round cell tumors.
“Small blue round cell turners” (SBRCTs) are a set of malignancies that have a particular proclivity for the pediatric age group. These tumors are notoriously difficult to distinguish by histologic evaluation alone, and in recent years a number of new immunohistochemical markers have emerged that can aid in the correct categorization of these lesions. Myogenin, a muscle-restricted nuclear transcription factor, has been demonstrated to be a highly sensitive and specific marker of rhabdomyosarcoma, and is superior to previous markers such as myoglobin, muscle actins, and desmin. The FLI-1 gene product is expressed as part of the EWS/FLI-1 novel chimeric protein that results from the t(11;22)(q24;q12) translocation that occurs in approximately two-thirds of cases of PNET/Ewings sarcoma. Immunohistochemical detection of the FLI-I gene product can thus complement detection of CD99/MIC2 for the positive identification of PNET/Ewings sarcoma. Markers of neuroblastoma include neural markers, such as chromogranin A, neurofilaments, and synaptophysin. Desmoplastic small round cell tumor (DSRCT) is a tumor with an unusual immunophenotype, including co-expression of cytokeratin, vimentin, and desmin; recent studies have also documented the use of antibodies to the WT-1 gene product as a marker of the chimeric EWS/WT-1 protein formed as a result of the t(11;22)(p13;q12) translocation that characterizes this unique tumor. In summary, there now exists a panel of antibodies defining immunohistochemical markers of individual SBRCTs that can identify rhabdomyosarcoma, PNET/Ewings sarcoma, neuroblastoma, and DSRCT with high sensitivity and specificity. (The J Histotechinol 25:229, 2002)
No takes yet. Share an insight, caveat, or question.
Gown et al. (2002) conducted a review in Small blue round cell tumors. Immunohistochemical markers was evaluated. A panel of immunohistochemical markers can identify individual small blue round cell tumors (rhabdomyosarcoma, PNET/Ewings sarcoma, neuroblastoma, and DSRCT) with high sensitivity and specificity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: